The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | CLL and COVID-19: patient outcomes
Lindsey Roeker, MD, CLL Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, outlines her ASH 2020 presentation on a worldwide study examining the outcomes for patients with chronic lymphocytic leukemia (CLL) and COVID-19. The study found that patients with CLL hospitalized for COVID-19 had a case fatality rate of 30-34% and advanced patient age at the time of COVID-19 diagnosis was an independent predictor for overall survival. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Lindsey Roeker, MD, has received research funding from the American Society of Hematology and Pfizer; has done consultancy work with AbbVie, AstraZeneca, Pharmacyclics, Vaniam Group and Verastem; and has a minority ownership interest in AbbVie and Abbott Laboratories.
